M. Haddad

发表

A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase

Sebastian Bonhoeffer, Colombe Chappey, Trevor Hinkley, 2011, Nature Genetics.

Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff

J. Jassem, W. Biernat, Weidong Huang, 2014, Clinical Cancer Research.

A Decade of HIV-1 Drug Resistance in the United States: Trends and Characteristics in a Large Protease/Reverse Transcriptase and Co-Receptor Tropism Database from 2003 to 2012

Joseph M. Volpe, C. Petropoulos, J. Whitcomb, 2014, Antiviral therapy.

Short communication A decade of HIV-1 drug resistance in the United States: trends and characteristics in a large

Joseph M. Volpe, C. Petropoulos, M. Haddad, 2014 .

Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravir.

N. Parkin, J. Hackett, G. Cloherty, 2013, Journal of virological methods.

Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.

J. Jassem, W. Biernat, T. Trojanowski, 2015, Neuro-oncology.

Trends in HIV-1 Reverse Transcriptase Resistance-Associated Mutations and Antiretroviral Prescription Data from 2003–2010

C. Gibbs, M. Haddad, Bill Guyer, 2012, Antiviral therapy.

Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival

John W. Adams, L. Bosserman, D. Yardley, 2015, Breast Cancer Research.

Exploring the Complexity of the HIV-1 Fitness Landscape

Sebastian Bonhoeffer, Christos J. Petropoulos, Gabriel E. Leventhal, 2012, PLoS genetics.

Estimating the Fitness Cost of Escape from HLA Presentation in HIV-1 Protease and Reverse Transcriptase

Sebastian Bonhoeffer, Christos J. Petropoulos, Mojgan Haddad, 2012, PLoS Comput. Biol..

HIV type 1 polymerase gene polymorphisms are associated with phenotypic differences in replication capacity and disease progression.

O. Laeyendecker, T. Quinn, M. Robb, 2014, The Journal of infectious diseases.

Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method

Mark C. Evans, Pham Phung, Agnes C. Paquet, 2014, BMC Bioinformatics.

Recombination Accelerates Adaptation on a Large-Scale Empirical Fitness Landscape in HIV-1

C. Petropoulos, S. Bonhoeffer, T. Hinkley, 2014, PLoS genetics.

Assessing Predicted HIV-1 Replicative Capacity in a Clinical Setting

Huldrych F. Günthard, Sebastian Bonhoeffer, Christos J. Petropoulos, 2011, PLoS pathogens.

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

C. Petropoulos, C. Singer, R. Horvat, 2013, Breast Cancer Research and Treatment.

Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy.

M. Buyse, J. Jassem, F. Piette, 2012, The oncologist.

Principal component analysis of general patterns of HIV-1 replicative fitness in different drug environments.

C. Petropoulos, S. Bonhoeffer, C. Chappey, 2010, Epidemics.

Predictive Biomarkers and Personalized Medicine Quantitative Measurements of Tumoral p 95 HER 2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab : Independent Validation of the p 95 HER 2 Clinical Cutoff

J. Jassem, W. Biernat, Weidong Huang, 2014 .

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer

Y. Bang, S. Im, Weidong Huang, 2012, PloS one.

John W. Adams, L. Bosserman, D. Yardley, 2015, Breast Cancer Research.

A Case-Based Reasoning System for Genotypic Prediction of HIV-1 Co-receptor tropism

Wei Huang, Eoin Coakley, Mark C. Evans, 2013, J. Bioinform. Comput. Biol..

Risk of Breast Cancer With CXCR4-Using HIV Defined by V3 Loop Sequencing

J. Goedert, K. Anastos, M. Young, 2015, Journal of acquired immune deficiency syndromes.

Abstract 2010: Immunosignature technology detects stage I lung cancer from a drop of serum

T. Tarasow, K. Sykes, M. Haddad, 2015 .

Prevalence in the Usa of Rilpivirine Resistance-Associated Mutations in Clinical Samples and Effects on Phenotypic Susceptibility to Rilpivirine and Etravirine

V. van Eygen, M. Haddad, J. Vingerhoets, 2014, Antiviral therapy.

Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method

T. Wrin, C. Petropoulos, M. Haddad, 2014, BMC Bioinformatics.

Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States.

E. Coakley, M. Haddad, J. Vingerhoets, 2011, AIDS Research and Human Retroviruses.

Feasibility analysis of a case-based reasoning system for automated detection of coronary heart disease from myocardial scintigrams

Gerold Porenta, Klaus-Peter Adlassnig, M. Haddad, 1997, Artif. Intell. Medicine.

Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.

J. Jassem, W. Biernat, T. Trojanowski, 2015, Neuro-oncology.